The industrial and academic rationale of CACO-2 cell models today

CACO-2 Cells and Their Uses

Volumn , Issue , 2011, Pages 1-30

  Berginc, Katja ^a   Zvonar, Alenka ^a   Gašperlin, Mirjana ^a   Krist, Albin ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Absorption.; CACO 2; Enzymes; Garlic; Interactions; Permeability; SMEDDS; Transporters

Indexed keywords

EID: 84892016194     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (99)

1. Bailey, CA; Bryla, P; Malick, AW. The use of the intestinal epithelial cell culture model, CACO-2, in pharmaceutical development. Advanced Drug Delivery Reviews, 1996; 22: 85-103.
2. Deferme, S; Annaert, P; Augustijns, P. In vitro screening models to assess intestinal drug absorption and metabolism. Drug absorption studies, Biotechnology: Pharmaceutical Aspects, 2008; Volume VII, 2: 182-215, DOI: 10.1007/978-0-387-74901-3_8.
3. Lennernäs, H; Palm, K; Fagerholm, U; Artursson, P. Comparison between active and passive drug transport in human intestinal epithelial (CACO-2) cells in vitro and human jejunum in vivo. International Journal of Pharmaceutics, 1996; 127: 103-107.
4. Artursson, P; Palm, K; Luthman, K. CACO-2 monolayers in experimental and theoretical predictions of drug transport. Advanced drug delivery reviews, 1996; 22: 67-84.
5. Kommuru, TR; Gurley, B; Khan, MA; Reddy IK. Self-emulsifying drug delivery systems (SEDDS) of Q10: formulation development and bioavailability assessment. International Journal of Pharmaceutics, 2001; 212: 233-246.
6. Gan, LSL; Thakker, DR. Application of the CACO-2 model in the design and development of orally active drugs: elucidation of the biochemical and physical barriers posed by the intestinal epithelium. Advanced Drug Delivery Reviews, 1997; 23: 77-98.
7. Quaroni, A; Hochman, J. Development of intestinal cell culture models for drug transport and metabolism studies. Adnavced Drug Delivery Reviews, 1996; 22: 3-52.
8. Pal, D; Mitra, AK. MDR- and CYP3A4-mediated drug-herbal interactions. Life Sciences, 2006; 78: 2131-2145.
9. Volpe, DA. Variability in CACO-2 and MDCK cell-based intestinal permeability assays. Journal of Pharmaceutical Sciences, 2008; 97: 712-725.
10. Hayeshi, R; Hilgendorf, C; Artursson, P; Augustijns, P; Brodin, B; Dehertogh, P; Fischer, K; Fossati, L; Hovenkamp, E; Korjamo, T; Masungi, C; Maubon, N; Mols, R; Müllertz, A; Mönkkönen, J; O'Driscoll, C; Oppers-Tiemissen, HM; Ragnarsson, EGE; Rooseboom, M; Ungell AL. Comparrison of drug transporter gene expression and functionality in CACO-2 cells from 10 different laboratories. European Journal of Pharmaceutical Sciences, 2008; 35: 383-396.
11. Maubon, N; Le Vee, M; Fossati, L; Audry, M; Le Ferrec, E; Bolze, S; Fardel, O. Analysis of drug transporter expression in human intestinal CACO-2 cells by real time PCR. Fundamental & Clinical Pharmacology, 2007; 21: 659-663.
12. Englund, G; Rorsman, F; Rönnblom, A; Karlbom, U; Lazorova, L; Gråsjö, J; Kindmark, A; Artursson, P. Regional levels of drug transporters along human intestinal tract: Co-expression of ABC and SLC transporters and comparison with CACO-2 cells. European Journal of Pharmaceutical Sciences, 2006; 29: 269-277.
13. Seithel, A; Karlsson, J; Hilgendorf, C; Björquist, A; Ungell, AL. Variability in mRNA expression of ABC and SLC transporters in human intestinal cells: Comparison between human segments and CACO-2 cells. European Journal of Pharmaceutical Sciences, 2006; 28: 291-299.
14. Sambuy, Y; De Angelis, I; Ranaldi, G; Scarino, ML; Stammati, A; Zucco, F. The CACO-2 cell line as a model of intestinal barrier: influence of cell and culture-related factors on CACO-2 cell functional characteristics. Cell Biology and Toxicology, 2005; 21: 1-26.
15. Shah, P; Jogani, V; Bagchi, T; Misra, A. Role of CACO-2 cell monolayers in prediction of intestinal drug absorption. Biotechnol Prog, 2006; 22: 186-198.
16. Hubatsch, I; Ragnarsson, EGE; Artursson, P. Determination of drug permeability and prediction of drug absorption in CACO-2 monolayers. Nature Protocols, 2007; 2: 2111-2119.
17. Guidance for Industry-Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on biopharmaceutical classification system http://www.fda.gov/ cde /guidance/index.htm (accessed September 2010).
18. Avdeef, A; Tam, KY. How well can the CACO-2/Madin-Darby Canine Kidney models predict effective human jejunal permeability? Journal of Medicinal Chemistry, 2010; 53: 3566-3584.
19. Yamashita, S; Furubayashi, T; Kataoka, M; Sakane, T; Sezaki, H; Tokuda, H. Optimized conditions for prediction of intestinal drug permeability using CACO-2 cells. European Journal of Pharmaceutical Sciences, 2000; 10: 195-204.
20. Ingels, FM; Augustijns, PF. Biological, Pharmaceutical, and Analytical considerations with the respect to the transport media used in the absorption screening system, CACO-2. Journal of Pharmaceutical Sciences, 2003; 92: 1545-1558.
21. Biganzoli, E; Cavenaghi, LA; Rossi, R; Brunati, MC; Nolli, ML. Use of a CACO-2 cell culture model for the characterization of intestinal absorption of antibiotics. Il Farmaco, 1999; 54: 594-599.
22. Kawashiro, T; Yamashita, K; Zhao, XJ; Koyama, R; Tani, M; Chiba, K; Ishizaki, T. A Study on the Metabolism of Etoposide and Possible Interactions with Antitumor or Supporting Agents by Human Liver Microsomes. The Journal of Pharmacology and Experimental Therapeutics, 1998; 286: 1294-1300.
23. Hande, KR; Krozely, MG; Greco, FA; Hainsworth, JD; Johnson, DH. Bioavailability of low-dose oral etoposide. Journal of Clinical Oncology, 1993; 11: 374-377.
24. Shugarts, S; Benet, LZ. The role of transporters in the pharmacokinetics of orally administered drugs. Pharmaceutical Research, 2009; 26: 2039-2054.
25. Proposal to waive in vivo bioequivalence requirements for the WHO model list of essential medicines immediate releaase, solid oral dosage forms. WHO. http://www.who.int/medicines/services/exper tcommittees/ pharmprep/QAS04_109Rev1_Waive_invivo_bioequiv.pdf (accessed Dec. 2010).
26. Custodio, JM; Wu, CY; Benet, LZ. Predicting drug disposition, absorption/elimination/ transporter interplay and the role of food on drug absorption. Advanced Drug Delivery Reviews, 2008; 60: 717-733.
27. Šturm, K; Takelj, S; Vadnjal, L; Kristl, A. Fluorescein transport properties across artificial lipid membranes, CACO-2 cell monolayers and rat jejunum. European Journal of Pharmaceutics and Bio pharmaceutics, 2007; 66: 281-285.
28. Balimane, PV; Chong, S. Evaluation of permeability and P-glycoprotein interactions: industry outlook, chapter 5: Biopharmaceutics application in drug development, editors Krishna R, Yu L, Springer 2008.
29. Hidalgo, IJ; Li, J. Carrier-mediated transport and efflux mechanisms in CACO-2 cells. Advanced Drug Delivery Reviews, 1996; 22: 53-66.
30. Dietrich, CG; Geier, A; Oude Elferink, RPJ. ABC of oral bioavailability: transporters as gatekeepers in the gut. Gut, 2003; 52: 1788-1795.
31. Pal, D; Mitra, AK. MDR- and CYP3A4-mediated drug-herbal interactions. Life Sciences, 2006; 78: 2131-2145.
32. Ioannides, C. Drug-phytochemical interactions. Inflammopharmacology, 2003; 11: 7-42.
33. Amagase, H. Clarifying the real bioactive constituents of garlic. Journal of Nutrition, 2006; 136: 716S-725S.
34. Barnes, J; Anderson, LA; Phillipson, J. Herbal medicines. 3rd ed. London Chicago, Pharmaceutical Press 2007.
35. Venkataramanan, R; Komoroski, B; Strom, S. In vitro and in vivo assessment of herb drug interactions. Life Sciences, 2006; 78: 2105-2115.
36. Klotz, U. Pharmacokinetics and drug metabolism in elderly. Drug Metabolism Reviews, 2009; 41: 67-76.
37. Drozdowski, L; Thomson, ABR. Aging and the intestine. World Journal of Gastroenterology, 2006; 12: 7578-7584.
38. Ahmed, T; Haboubi, N. Assessment and management of nutrition in older people and its importance to health. Clinical Interventions in Aging, 2010; 5: 207-216.
39. Agarwal, KC. Therapeutic actions of garlic constituents. Medicinal Research Reviews, 1996; 16: 111-124.
40. Ejaz, S; Woong, LC; Ejaz, A. Extract of garlic (Allium sativum) in cancer chemoprevention. Experimental Oncology, 2003; 25; 93-97.
41. Zhou, S; Gao, Y; Jiang, W; Huang, M; Xu, A; Paxton, JW. Interactions of herbs with Cytochrome P450. Drug Metabolism Reviews, 2003; 35: 35-98.
42. Borrelli, F; Capasso, R; Izzo, AA. Garlic (Allium sativum L.): adverse effects and drug interactions in humans. Molecular Nutrition & Food Research, 2007; 51: 1386-1397.
43. Abebe, W. Herbal medication: potential for adverse interactions with analgesic drugs. Journal of Clinical Pharmacy and Therapeutics, 2002; 27: 391-401.
44. Banerjee, SK; Maulik, SK. Effect of garlic on cardiovascular disorders: a review. Nutrition Journal, 2002; 1: 4-18.
45. Hu, Z; Yang, X; Ho, PCL; Chan, SY; Heng, PWS; Chan, E; Duan, W; Koh, HL; Zhou, S. Herb-drug interactions, a literature review. Drugs, 2005; 65: 1239-1282.
46. Izzo, AA. Herb-drug interactions: an overview of the clinical evidence. Fundamental & Clinical Pharmacology, 2004; 19: 1-16.
47. Williamson, EM. Drug interactions between herbal and prescribed medicines. Drug Safety, 2003; 26: 1075-1092.
48. Mills, E; Montori, V; Perri, D; Phillips, E; Koren, G. Natural health-HIV drug interactions: a systematic overview. International Journal of STD & AIDS, 2005; 16: 181-186.
49. Fugh-Bergman, A; Ernst, E. Herb-drug interactions: review and assessment of report reliability. British Journal of Clinical Pharmacology, 2001; 52: 587-595.
50. Coecke, S; Rogiers, V; Bayliss, M; Castell, J; Doehmer, J; Fabre, G; Fry, J; Kern, A; Westmoreland, J. The use of long-term hepatocyte cultures for detecting induction of drug metabolizing enzymes: the current status. Alternatives to Laboratory Animals, 1999: 27: 579-638.
51. Brandon, EFA; Raap, CD; Meijerman, I; Beijnen, HS; Schellens, JHM. An update on in vitro methods in human hepatic drug biotransformation research: pros and cons. Toxicology and Applied Pharmacology, 2003; 189: 233-246.
52. Piscitelli, SC; Burnstein, AH; Welden, N; Gallicano, KD; Falloon, J. The effect of garlic supplements on the pharmacokinetics of saquinavir. Clinical Infectious Diseases, 2002; 34: 234-238.
53. Berginc, K; Takelj, S; Kristl, A. In vitro interactions between aged garlic extract and drugs used for the treatment of cardiovascular and diabetic patients. European Journal of Nutrition, 2010; 49(6): 373-384.
54. Berginc, K; Trdan, T; Trontelj, J; Kristl, A. HIV protease inhibitors: garlic supplements and first-pass intestinal metabolism impact on the therapeutic efficacy. Biopharmaceutics & drug dispotition, 2010; 31: 495-505.
55. Tang, C; Prueksaritanont, T. Use of in vivo animal models to assess pharmacokinetic drug-drug interactions. Pharmaceutical Research, 2010; 27: 1772-1787.
56. Taipalensuu, J; Törnblom, H; Lindberg, G; Einarsson, C; Sjöqvist, F; Melhus, H; Garberg, P; Sjöström, B; Lundgren, B; Artursson, P. Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial CACO-2 cell monolayers. The Journal of Pharmacology and Experimental Therapeutics, 2001; 299: 164-170.
57. Haimeur, A; Conseil, G; Deeley, RG; Cole, SP. The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. Current Drug Metabolism, 2004; 5: 21-53.
58. Masereel, B; Pochet, L; Laeckmann, D. An overview of inhibitors of Na/H exchanger. European Journal of Medicinal Chemistry, 2003; 38: 547-554.
59. Anderle, P; Huang, Y; Sadee, W. Intestinal membrane transport of drugs and nutrients: genomics of membrane transporters using expression microarrays. European Journal of Pharmaceutical Sciences, 2004; 21: 17-24.
60. Martin, C; Berridge, G; Higgins, CF; Mistry, P; Charlton, P; Callagan, R. Communication between multiple drug binding sites on P-glycoprotein. Molecular Pharmacology, 2000; 58: 624-632.
61. Gerk, PM; Vore, M. Regulation of expression of the multipledrug resistancee-associated protein 2 (MRP-2) and its role in drug disposition. Journal of Pharmacology & Experimental Therapeutics, 2002; 302: 407-415.
62. Steffansen, B; Nielsen, CU; Brodin, B; Eriksson, AH; Andersen, R; Frokjaer, S. Intestinal solute carriers: an overview of trends and strategies for improving oral absorption. European Journal of Pharmaceutical Sciences, 2004; 21: 3-16.
63. Berginc, K; Takelj, S; Uršic, D; Kristl, A. Aged garlic extract stimulates P-glycoprotein and Multidrug resistance associated protein 2 mediated effluxes. Biological & Pharmaceutical Bulletin, 2009; 32: 694-699.
64. Shugarts, S; Benet, LZ. The role of transporters in the pharmacokinetics of orally administered drugs. Pharmaceutical Research 2009; 26: 2039-2054.
65. Benet, LZ. Using the BDDCS to predict when metabolism and drug transport influence the disposition of a drug. AAPS workshop on drug transporters in ADME: from the bench to the bedside, March 8, 2005.
66. Wang, YH; Chao, PDL; Hsiu, SL; Wen, KC; Hou. YC. Lethal quercetin-digoxin interactions in pigs. Life Sciences, 2004; 74: 1191-1197.
67. Langman, P; Zilly, M; Winzer, R; Klinker, H. Therapeutic drug monitoring: a tool to individualize highly active antiretroviral therapy in HIV infected patients. Current Pharmaceutical Analysis, 2006; 2: 205-217.
68. Petit, F; Fromenty, B; Owen, A; Estaquier, J. Mitochondria are sensors for HIV drugs. Trends in Pharmacological Sciences, 2005; 26: 258-264.
69. Zvonar, A; Berginc, K; Kristl, A; Gašperlin, M. Microencapsulation of self-microemulsifying system: improving solubility and permeability of furosemide. International Journal of Pharmaceutics, 2010; 388: 151-158.
70. Xianyi, S; Guijun, Y; Yunjuan, W; Juncan, L; Xiaoling, F. Effect of self-emulsifying drug delivery systems containing Labrasol on tight junctions in CACO-2 cells. European Journal of Pharmaceutical Sciences; 2005; 24: 477-486.
71. Daham, A; Hoffman, A. The effects of different lipid based formulations on the oral absorption of lipophilic drugs: the ability of in vitro lipolysis and consecutive ex vivo intestinal permeability data to predict in vivo bioavailability in rats. European Journal Pharmaceutics and Biopharmaceutics, 2007; 67: 96-105.
72. Perng, CH; Kearney, AS; Patel, K; Palepu, NR; Zuber, G. Investigation of formulation approaches to improve dissolution of SB-210661, a poorly soluble 5-lipooxigenase inhibitor. International Journal of Pharmaceutics, 1998; 176: 31-38.
73. Homar, M; Dreu, R; Kerc, J; Gašperlin, M. Preparation and evaluation of celecoxib-loaded microcapsules with self-microemulsifying core. Journal of Microencapsulation, 2009; 26: 479-484.
74. Zvonar, A; Rozman, B; Bešter-Rogac, M; Gašperlin, M. The influence of microstructure on celecoxib release from a pharmaceutically applicable system: Mygliol 812/Labrasol/Plurol oleiquer/water mixtures. Acta Chimica Slovenica, 2009; 56: 131-138.
75. Dolenc, A; Govedarica, G; Dreu, R; Kocbek, P; Srcic, S; Kristl, J. Nanosized particles of orlistat with enhanced in vitro dissolution rate and lipase inhibition. International Journal of Pharmacetics, 2010; 396: 149-155.
76. Porter, CJH; Trevaskis, NL; Charman, WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nature Reviews Drug Discovery, 2007; 6: 231-248.
77. Pouton, CW. Lipid formulations for oral administration of drugs: non-emulsifying, self emulsifying, and `self microemulsifying` drug delivery systems. European Journal of Pharmaceutical Sciences, 2000; 11 (Suppl. 2): S93-S98.
78. Pouton, CW. Formulation of poorly water-soluble drugs for oral administraniton: physicochemical and physiological issues and the lipid formulation classification system. European Journal of Pharmaceutical Sciences, 2006; 29: 278-287.
79. Shah, NH; Carvajl, MT; Patel, PI; Infeld, MH; Malick, AW. Self-emulsifying drug delivery systems (SEDDS) with polyglycolized glycerides for improving in vitro dissolution and oral absorption of lipophilic drugs. International Journal of Pharmaceutics, 1994; 106: 15-23.
80. Constantinides, PP. Lipid microemulsions for improving drug dissolution and oral absorption: Physical and biopharmaceutical aspects. Pharmaceutical Research, 1995; 12(11): 1561-1572.
81. Neslihan Gursoy, R; Benita, S. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomedicine & Pharmacotherapy, 2004; 58: 173-182.
82. Hauss, DJ. Oral lipid-based formulations. Advanced Drug Delivery Reviews, 2007; 59: 667-676.
83. Pouton, CW; Porter, CJH. Formulation of lipid-based delivery systems for oral administration: materials, methods and strategies. Advanced Drug Delivery Reviews, 2008; 60: 625-637.
84. O'Driscoll, CM; Griffin, BT. Biopharmaceutical challanges associated with drugs with low aqueous sulubility-the potential impact of lipid-based formulations. Advanced Drug Delivery Reviews, 2008; 60: 617-624.
85. Mei-Ling, C. Lipid excipients and delivery systems for pharmaceutical development: a regulatory perspective. Advanced Drug Delivery Reviews, 2008; 60: 768-777.
86. Seebaluck, F; Ashhord, MB; O'Driscoll, CM. The effects of pluronics block copolymers and cremophor EL on intestinal lipoprotein processing and the potential link with P-glycoprotein in CACO-2 cells. Pharmaceutical Research, 2003; 20: 1085-1092.
87. Gajjar, R; Lo, CM; Tso, P. Physiological processes governing gastrointestinal absorption of lipids and lipophilic xenobiotics, in: Hauss DJ(Ed.), Oral lipid-based formulations: enhancing the bio availability of poorly water soluble drugs, Informa Healthcare, Inc., New York, 2007, pp. 207-239.
88. Trevaskis, NL; Charman, WN; Porter, CJH. Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update. Advanced Drug Delivery Reviews, 2008; 60: 702-716.
89. Dahan, A; Hoffman, A. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs. Journal of Controlled Release, 2008; 129: 1-10.
90. Buyukozturk, F; Benneneyan, JC; Carrier, RL. Impact of emulsion-based drug delivery systems on intestinal permeability and drug release kinetics. Journal of Controlled Release, 2010; 142: 22-30.
91. O'Driscoll, CM. Lipid-based formulations for intestinal lymphatic delivery. Mini review. European Journal of Pharmaceutical Sciences, 2002; 15: 405-415.
92. Grove, M. Lipid Self-microemulsifying drug delivery systems, in: Hauss DJ (Ed.), Oral lipid-based formulations: enhancing the bioavailability of poorly water soluble drugs, Informa Healthcare, Inc., New York, 2007, pp. 107-127.
93. Fatouros, DM; Karpf, DM; Nielsen, FS; Mullertz, A. Clinical studies with oral lipid based furmulations of poorly soluble compounds. Therapeutics and Clinical Risk Management, 2007; 3(4): 591-604.
94. Chakraborty, S; Shukla, D; Mishra, B; Singh, S. Lipid-An emerging platform for oral delivery of drugs with poor bioavailability. European Journal of Pharmaceutics and Biopharmaceutics, 2009; 73: 1-15.
95. O'Driscoll, CM. Intestinal lymphatic targeting of drugs. STP Pharma Sciences, 2003; 13: 17-25.
96. Sha, X; Yan, G; Wu, Y; Li, J; Fang, X. Effect of self-microemulsifying drug delivery systems containing Labrasol on tight junctions in CACO-2. European Journal of Pharmaceutical Sciences, 2005; 24: 477-486.
97. Cano-Cebrián, MJ; Zornoza, T; Granero, L; Polache, A. Intestinal absorption enhancement via the paracellular route by fatty acids, chitosan and others: a target for drug delivery. Current Drug Delivery, 2005; 2: 9-22.
98. Constantinides, PP; Kishor, M; Wasan, KM. Lipid formulation strategis for enhancing intestinal transport and absorption of P-glycoprotein (P-gp) substrate drugs: in vitro/in vivo case studies. Review. Journal of Pharmaceutical Sciences, 2007; 96: 235-248.
99. Goole, J; Lindley, DJ; Roth, W; Carl, SM; Amighi, K; Kauffmann, JM; Knipp, GT. The effects of excipients on transporter mediated absorption. Review. Internation Journal of Pharmaceutics 2010; 393: 17-31.